NCT04225026 2023-03-23
Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer
Galera Therapeutics, Inc.
Phase 2 Terminated
Galera Therapeutics, Inc.
Radiation Therapy Oncology Group
OHSU Knight Cancer Institute